Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)

Cardiac Dysfunction Clinical Trial

Official title:
Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)

Status Completed

Clinical Trial Summary

Extracorporeal membrane oxygenation (ECMO) is the device which increases the supply of oxygen to the body tissues in vitro and to assist in heart and lung function. Venoarterial (VA) ECMO is used in patients with cardiogenic shock, cardiac arrest, ventricular arrhythmia and is able to secure a time to self-recovery by reducing the excessive stimulation applied to the heart. However, in ECMO patients, pharmacokinetics of drugs are changing such as increased volume of distribution (Vd) or decreased clearance (CL). For this reason, it is hard to provide the best treatment in ECMO patients. The study is to evaluate whether the PK of drugs is influenced by VA ECMO and to recommend the optimal dosing strategies for proposed drugs in adult patients receiving VA ECMO.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cardiac Dysfunction

Clinical Trial Details

NCT number	NCT02581280
Study type	Observational
Source	Yonsei University
Contact
Status	Completed
Phase
Start date	December 2014
Completion date	January 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02320539` - MicroRNA Diagnostics in Subarachnoid Hemorrhage 2	N/A
Terminated	`NCT03085420` - Cardiac Arrhythmias and Dysfunction in the Pediatric Burn Patient	N/A
Recruiting	`NCT05806138` - A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction	Phase 2
Terminated	`NCT04433546` - Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).	Phase 2
Recruiting	`NCT03790943` - Cardiac Dysfunction in Childhood Cancer Survivors
Recruiting	`NCT05659589` - Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury	N/A
Completed	`NCT03866564` - Football Players Health Study In Person Assessments Study
Recruiting	`NCT02144766` - Prevention of Myocardial Dysfunction and Injury Resulting From Salter Innominate Osteotomy by Caudal Block	Phase 4